Immix Biopharma Plans to Use Net Proceeds From Offering for NXC-201 Clinical Trials, Working Capital, General Purposes >IMMX
Immix Biopharma Plans to Use Net Proceeds From Offering for NXC-201 Clinical Trials, Working Capital, General Purposes >IMMX
Immix Biopharma 计划将发行的净收益用于 NXC-201 临床试验、营运资金、一般用途 >IMMX
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册